Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens

Abstract

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

“…The primary objective of the trial was to assess the safety and feasibility of DC vaccination, therefore conclusions about the clinical efficacy are made with caution. Nevertheless, the clinical response was seen to be comparable with responses observed in previous prostate cancer DC vaccine studies (48). …”

Long Non-Coding RNA MEG3 Inhibits Cell Proliferation and Induces Apoptosis in Prostate Cancer

“…About one million new cases are diagnosed with prostate cancer every year and it accounts for nearly 10% of all new cancer cases in men worldwide [4,5]. In addition, about one-third of patients with organ-confined prostate cancer fail local therapy and progress to advanced-staged or metastatic disease in 10 years [6]. Metastatic prostate cancer may finally develop into androgen-independent prostate cancer and hormone refractory prostate cancer, which is the major cause of death in prostate cancer patients [7,8,9].…”

Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies

“…The introduction of sipuleucel-T, though groundbreaking for its approval by the FDA, has only resulted in a modest improvement in prostate cancer outcomes [71]. While the goal of treatment specificity is to minimize toxicity, this comes at a cost of reduction in treatment effect.…”